When a patient is critically ill, giving their doctor the right information at the right time can mean the difference between life and death. At Novus Diagnostics, we are developing a ground-breaking diagnostics technology to provide rapid answers right at the patient’s bedside. Our first product, SepTec, will help tackle the global challenge of sepsis which kills more than 11 million people every year. Our technology platform brings together novel electrochemical sensors, centrifugal microfluidics and automated sample processing and analysis to diagnose and characterise a blood stream infection within 15 minutes; enabling earlier lifesaving targeted treatment. We are a young, driven company working to solve a major global health challenge. We are building a team of people who are excited by this challenge and committed to making a real difference through their work.
Location: Ireland, Dublin
Employees: 11-50
Total raised: $7.64M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 07.04.2025 | Irrus Inve... | irrusinves... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.01.2025 | - | $4.72M | - |
| 13.01.2021 | - | $2.92M | - |
Mentions in press and media 4
| Date | Title | Description |
| 24.04.2025 | Novus Diagnostics Appoints Margrit Schwarz to expanded Board of Directors | Dr Margrit Schwarz - Novus Diagnostics Novus Diagnostics logo Novus Diagnostics Appoints Margrit Schwarz to expanded Board of Directors to help accelerate commercialisation of rapid sepsis diagnostic platform I am pleased to join Novus Diag... |
| 15.01.2025 | Novus Diagnostics Secures €4.6M in Equity Financing to Revolutionize Rapid Point-of-Care Diagnostics | Novus Diagnostics CEO Keith O'Neill speaking at the 2024 American Irish Innovation Summit in Dublin Investment will accelerate the development of Novus' rapid point of care diagnostic technology and their groundbreaking 15 minute point of c... |
| 25.10.2024 | Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform | DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategi... |
| - | Novus Diagnostics | “Novus Diagnostics” |